A multi-center, double-blind, randomized, placebo- and positive-controlled phase II clinical study of benvitimod for the treatment of atopic dermatitis.
10.1097/CM9.0000000000002489
- Author:
Lin CAI
1
;
Yan ZHAO
1
;
Min ZHENG
2
;
Furen ZHANG
3
;
Qing SUN
4
;
Quanzhong LIU
5
;
Jin HU
6
;
Juan SHEN
7
;
Jianzhong ZHANG
1
Author Information
1. Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
3. Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong 250022, China.
4. Department of Dermatology, Shandong University Qilu Hospital, Jinan, Shandong 250012, China.
5. Department of Dermatology, Tianjin Medical University General Hospital, Tianjin 300052, China.
6. Beijing Wenfeng Tian Ji Pharma Ltd., Beijing 100044, China.
7. Zhonghao Pharmaceutical, Zhongshan, Guangdong 528437, China.
- Publication Type:Letter
- MeSH:
Humans;
Dermatitis, Atopic/drug therapy*;
Resorcinols/therapeutic use*;
Stilbenes/therapeutic use*;
Double-Blind Method;
Treatment Outcome;
Severity of Illness Index
- From:
Chinese Medical Journal
2023;136(2):251-252
- CountryChina
- Language:English
